Condition: Age-related Wet Macular Degeneration · Sponsor: Caregen Co. Ltd.
This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration
This description comes directly from the study's public registry record.
Ishita Trivedi · +1- 609-594-6709 · ishita.trivedi@cbcc.global
Eldho Jose · eldho.jose@cbcc.global
Always discuss trial participation with your own doctor first.
| CBCC Global Research Site:005 | Manchester, Connecticut, United States | Recruiting |
| CBCC Global Research Site:006 | Deerfield Beach, Florida, United States | Recruiting |
| CBCC Global Research Site:001 | Augusta, Georgia, United States | Recruiting |
| CBCC Global Research Site:004 | Carmel, Indiana, United States | Recruiting |
| CBCC Global Research Site:003 | Fargo, North Dakota, United States | Recruiting |
| CBCC Global Research Site:002 | Erie, Pennsylvania, United States | Recruiting |
| CBCC Global Research Site:007 | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06132035